[go: up one dir, main page]

WO2007058990A3 - Therapy using cytokine inhibitors - Google Patents

Therapy using cytokine inhibitors Download PDF

Info

Publication number
WO2007058990A3
WO2007058990A3 PCT/US2006/043896 US2006043896W WO2007058990A3 WO 2007058990 A3 WO2007058990 A3 WO 2007058990A3 US 2006043896 W US2006043896 W US 2006043896W WO 2007058990 A3 WO2007058990 A3 WO 2007058990A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
therapy
cytokine inhibitors
autoimmune diseases
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/043896
Other languages
French (fr)
Other versions
WO2007058990A2 (en
Inventor
Nancy Delaet
Christopher Larson
Kent Pryor
Bonnie Hepburn
Robin Allgren
Bernard D King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kemia Inc
Original Assignee
Kemia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemia Inc filed Critical Kemia Inc
Publication of WO2007058990A2 publication Critical patent/WO2007058990A2/en
Publication of WO2007058990A3 publication Critical patent/WO2007058990A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to methods of treating autoimmune diseases, which comprise the administration of a cytokine inhibitor alone or in combination with known therapeutics or treatments. The invention also relates to pharmaceutical compositions and dosing Tegimens. In particular, the invention relates to the use of cytokine inhibitors, optionally in conjunction with other therapies, for the treatment of autoimmune diseases, more particularly pemphigus.
PCT/US2006/043896 2005-11-14 2006-11-13 Therapy using cytokine inhibitors Ceased WO2007058990A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73662105P 2005-11-14 2005-11-14
US60/736,621 2005-11-14
US78594306P 2006-03-24 2006-03-24
US60/785,943 2006-03-24

Publications (2)

Publication Number Publication Date
WO2007058990A2 WO2007058990A2 (en) 2007-05-24
WO2007058990A3 true WO2007058990A3 (en) 2007-12-06

Family

ID=38049183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/043896 Ceased WO2007058990A2 (en) 2005-11-14 2006-11-13 Therapy using cytokine inhibitors

Country Status (1)

Country Link
WO (1) WO2007058990A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1986633E (en) 2006-02-10 2014-11-05 Summit Corp Plc Treatment of duchenne muscular dystrophy
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
TWI398252B (en) * 2006-05-26 2013-06-11 Novartis Ag Pyrrolopyrimidine compounds and their uses
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200831104A (en) 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
WO2008043019A1 (en) 2006-10-04 2008-04-10 Pharmacopeia, Inc 8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
EA015952B1 (en) 2007-05-03 2011-12-30 Пфайзер Лимитед 2-pyridinecarboxamide derivatives as sodium channel modulators
CA2685540C (en) 2007-08-03 2018-10-16 Graham Michael Wynne Drug combinations for the treatment of duchenne muscular dystrophy
EP2331525A4 (en) 2008-08-11 2013-01-02 Harvard College HALOFUGINONE ANALOGUES FOR THE INHIBITION OF ARNT SYNTHÉTASES AND USES THEREOF
US8685980B2 (en) 2008-08-22 2014-04-01 Novartis Ag Pyrrolopyrimidine compounds and their uses
UY33227A (en) 2010-02-19 2011-09-30 Novartis Ag PIRROLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF THE CDK4 / 6
US8815265B2 (en) 2010-06-30 2014-08-26 Avon Products, Inc. Cosmetic use of N-substituted sulfonyloxybenzylamines and related compounds
WO2013106702A1 (en) 2012-01-13 2013-07-18 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
SG11201804587QA (en) 2015-12-15 2018-06-28 Astrazeneca Ab Isoindole compounds
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
PT3558997T (en) 2016-12-20 2021-04-13 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
US11034654B2 (en) 2017-06-14 2021-06-15 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ROR-gamma modulators
US11667651B2 (en) 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
ES2962605T3 (en) 2018-02-26 2024-03-20 Gilead Sciences Inc Substituted pyrrolizine compounds as inhibitors of HBV replication
PT3802517T (en) 2018-06-07 2023-03-20 Idorsia Pharmaceuticals Ltd Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis
WO2019237125A1 (en) 2018-06-08 2019-12-12 The General Hospital Corporation Inhibitors of prolyl-trna-synthetase
TW202112767A (en) 2019-06-17 2021-04-01 美商佩特拉製藥公司 Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
KR102732033B1 (en) * 2019-07-26 2024-11-20 아주대학교산학협력단 Novel Small molecule Compound Inhibiting TLR7 and TLR9 Signaling Pathways and Uses Thereof
CN119923385A (en) 2022-02-14 2025-05-02 埃克森特治疗公司 Inhibitors of RNA helicase DHX9 and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236193A1 (en) * 2001-10-11 2003-12-25 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US20040166111A1 (en) * 2002-10-24 2004-08-26 Zehra Kaymakcalan Low dose methods for treating disorders in which TNFalpha activity is detrimental
US6797267B2 (en) * 1997-11-05 2004-09-28 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
US20040198697A1 (en) * 1992-05-01 2004-10-07 Cohen Irun R. Compositions for the regulation of cytokine activity
US20050107399A1 (en) * 2003-09-11 2005-05-19 Kemia, Inc. Cytokine inhibitors
US20050176687A1 (en) * 2001-06-29 2005-08-11 Alain Moussy Use of tyrosine kinase inhibitors for treating autoimmune diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198697A1 (en) * 1992-05-01 2004-10-07 Cohen Irun R. Compositions for the regulation of cytokine activity
US6797267B2 (en) * 1997-11-05 2004-09-28 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
US20050176687A1 (en) * 2001-06-29 2005-08-11 Alain Moussy Use of tyrosine kinase inhibitors for treating autoimmune diseases
US20030236193A1 (en) * 2001-10-11 2003-12-25 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US20040166111A1 (en) * 2002-10-24 2004-08-26 Zehra Kaymakcalan Low dose methods for treating disorders in which TNFalpha activity is detrimental
US20050107399A1 (en) * 2003-09-11 2005-05-19 Kemia, Inc. Cytokine inhibitors

Also Published As

Publication number Publication date
WO2007058990A2 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
WO2007058990A3 (en) Therapy using cytokine inhibitors
WO2007146712A3 (en) Therapy using cytokine inhibitors
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
TN2011000200A1 (en) Combination therapy with peptide epoxyketones
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
WO2005117954A3 (en) Compositions and methods for treatment of neovascular diseases
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
HK1198869A1 (en) Combination treatments for hepatitis c
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
WO2006091862A3 (en) Cytokine inhibitors and their use in therapy
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
WO2008112773A3 (en) Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2004093813A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies
WO2010065069A3 (en) Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
WO2011113000A8 (en) Novel ester containing compositions and methods
EA200901062A1 (en) USING INHIBITORS OF SOLUBLE EPOXYDHYDROLASE FOR THE PREVENTION AND TREATMENT OF METABOLIC SYNDROME AND RELEVANT DISORDERS
WO2005099749A3 (en) Methods for controlling angiogenesis and cell proliferation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC DATED 08.09.2008.

122 Ep: pct application non-entry in european phase

Ref document number: 06837388

Country of ref document: EP

Kind code of ref document: A2